Sagimet Biosciences (SGMT) | Stock Overview & Key Data
Sagimet Biosciences Performance Comparison
Stock Range
Today's Range
Low: $7.15
High: $7.55
on October 3, 2025
52 Week Range
Low: $1.73
High: $11.41
on April 7, 2025
on July 25, 2025
All-Time High: $20.71 on January 22, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$249.3M
EPS
-1.86
P/E Ratio (TTM)
-5.03
Forward P/E
-2.05
P/B Ratio
1.80
PEG Ratio
-0.18
Div. Yield
N/A
ROE
-37.89%
Beta
3.270
Debt to Equity
0.12
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-25.61%
Return on Equity (TTM)
-37.89%
EBITDA
$0
Net Income (TTM)
$-59.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences SGMT | 249.31M Micro-cap | -0.68% | -0.68% | -11.64% | 221.15% | 62.36% | 78.24% | -54.27% | -54.27% |
| Vertex VRTX | 103.40B Large-cap | 4.55% | 1.68% | -12.25% | -16.68% | -0.61% | -11.42% | 36.61% | 49.40% |
| Regeneron REGN | 63.78B Large-cap | 6.40% | 6.42% | 9.62% | -1.74% | -16.11% | -40.76% | -16.94% | -0.34% |
| Invivyd IVVD | 247.29M Micro-cap | 3.57% | 11.54% | 56.76% | 110.91% | 141.67% | 22.11% | -63.64% | -94.44% |
| Third Harmonic Bio THRD | 242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.85% | -51.27% | -53.82% | -70.11% | -70.11% |
| Heron Therapeutics HRTX | 241.98M Micro-cap | 9.09% | -0.75% | -40.00% | -38.32% | -17.50% | -37.74% | -68.50% | -91.64% |
Ownership & Short Interest
Insider Ownership
9.81%
Institutional Ownership
29.16%
Shares Short
3M
Short Ratio
5.61
Short % of Shares Outstanding
10.81%
Average 10-Day Volume
443K
Average 90-Day Volume
471K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SGMT's 52-week high and low?
- In the last 52 weeks, Sagimet Biosciences reached a high of $11.41 (on July 25, 2025) and a low of $1.73 (on April 7, 2025).
- What is the market cap and P/E ratio for SGMT?
- Curious about Sagimet Biosciences's size and valuation? Its market capitalization stands at 249.31M. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.03, and the forward P/E (looking ahead) is -2.05.
- Does SGMT pay dividends? If so, what's the yield?
- As for dividends, Sagimet Biosciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sagimet Biosciences's main competitors or similar companies to consider before investing?
When looking at Sagimet Biosciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX103.40B Healthcare Biotechnology -11.42% 36.61% Regeneron
REGN63.78B Healthcare Biotechnology -40.76% -16.94% Invivyd
IVVD247.29M Healthcare Biotechnology 22.11% -63.64% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% Heron Therapeutics
HRTX241.98M Healthcare Biotechnology -37.74% -68.50% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sagimet Biosciences Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Sagimet Biosciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -37.89%, the Debt to Equity ratio from the most recent quarter is 0.12, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for SGMT?
- Looking at Sagimet Biosciences's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of SGMT stock is held by insiders and institutions?
- Wondering who owns Sagimet Biosciences stock? Company insiders (like executives and directors) hold about 9.81% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 29.16%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.